---
title: "Virtual trials quantify stroke versus bleeding trade-offs of oral anticoagulation in atrial fibril"
id: "medrxiv-12-risk-benefit-assessment-of-oral-anticoagulation-in-atrial-fibrillation-using"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-12-risk-benefit-assessment-of-oral-anticoagulation-in-atrial-fibrillation-using"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1?rss=1"
published_at: "2026-11-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Virtual trials quantify stroke versus bleeding trade-offs of oral anticoagulation in atrial fibril
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-12-risk-benefit-assessment-of-oral-anticoagulation-in-atrial-fibrillation-using
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1?rss=1)
- **Published At:** 2026-11-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors developed a state-transition Markov-like model to simulate lifetime courses of **atrial fibrillation**, stroke, major bleeding, and death across virtual populations. - The model synthesized multiple clinical data sources and reproduced observed stroke and bleeding incidence across clinical scenarios, according to the preprint. - Systematic screening with long-term continuous rhythm monitoring (LT-CRM) plus **OAC** reduced stroke risk at CHA2DS2-VA = 2 (HR 0.92, 95% CI 0.88–0.96) while increasing bleeding risk (HR 1.17, 95% CI 1.07–1.27) versus no screening. - Time-to-benefit (stroke reduction) was shorter than time-to-harm (bleeding) for CHA2DS2-VA ≥ 4, but the opposite held at CHA2DS2-VA = 0, per model outputs. - A rhythm-guided, time-delimited “pill-in-pocket” **OAC** strategy showed no difference in stroke or mortality compared with continuous **OAC** (HR 1.03, 95% CI 0.91–1.16) but reduced bleeding risk in patients with elevated baseline bleeding risk (HR 0.81, 95% CI 0.68–0.96), not in the baseline cohort. - Sensitivity analyses indicated that net risk-benefit of screening or pill-in-pocket approaches depends on **OAC** adherence and bleeding risk assumptions. - The authors noted this as the first virtual implementation of an ongoing rhythm-guided **OAC** trial and propose that virtual clinical trials can inform trial design; code and model will be deposited on the authors' GitHub. - The report is a preprint and has not undergone peer review; the authors caution it should not guide clinical practice. Competing interests and data availability are declared in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=mgJB4CQVjcXS_8vYRNcEeHwiXGS69NhQIQn6WVbYDnY-1793929582.197052-1.2.1.1-wzkcEniCPs1Icet4mZ_t6oMNkcWFEBknEvZXdKXl7Nu4pUqV1fFBlye0Tk.w3wjH) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Risk-benefit assessment of oral anticoagulation in atrial fibrillation using virtual clinical trials Minsi Cai, Fateme Farahani, [ View ORCID Profile](http://orcid.org/0000-0002-2581-070X)Michiel Rienstra, [ View ORCID Profile](http://orcid.org/0000-0003-4306-8294)Stefano Severi, [ View ORCID Profile](http://orcid.org/0000-0003-1073-5337)Harry J.G.M. Crijns, [ View ORCID Profile](http://orcid.org/0000-0003-1532-3315)Ulrich Schotten, [ View ORCID Profile](http://orcid.org/0000-0002-1418-108X)Jordi Heijman doi: https://doi.org/10.64898/2026.11.04.26367324 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Minsi Cai 1 Universiteit Maastricht Cardiovascular Research Institute Maastricht; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Minsi%2BCai%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cai%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMinsi%2BCai%2B) Fateme Farahani 2 Universita degli Studi di Bologna - Campus di Cesena; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Fateme%2BFarahani%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Farahani%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFateme%2BFarahani%2B) Michiel Rienstra 3 Department of Cardiology, University of Groningen, University Medical Center Groningen; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michiel%2BRienstra%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rienstra%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichiel%2BRienstra%2B) * [ORCID record for Michiel Rienstra](http://orcid.org/0000-0002-2581-070X "Open in new tab") Stefano Severi 4 University of Bologna; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stefano%2BSeveri%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Severi%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStefano%2BSeveri%2B) * [ORCID record for Stefano Severi](http://orcid.org/0000-0003-4306-8294 "Open in new tab") Harry J.G.M. Crijns 5 Maastricht University Medical Centre,; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Harry%2BJ.G.M.%2BCrijns%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Crijns%20HJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHarry%2BJ.G.M.%2BCrijns%2B) * [ORCID record for Harry J.G.M. Crijns](http://orcid.org/0000-0003-1073-5337 "Open in new tab") Ulrich Schotten 1 Universiteit Maastricht Cardiovascular Research Institute Maastricht; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ulrich%2BSchotten%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schotten%20U&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AUlrich%2BSchotten%2B) * [ORCID record for Ulrich Schotten](http://orcid.org/0000-0003-1532-3315 "Open in new tab") Jordi Heijman 6 Medizinische Universitat Graz * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jordi%2BHeijman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Heijman%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJordi%2BHeijman%2B) * [ORCID record for Jordi Heijman](http://orcid.org/0000-0002-1418-108X "Open in new tab") * For correspondence: jordi.heijman@medunigraz.at * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1339216/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1339216/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1339216/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1339216/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1339216/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Abstract Background: Oral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF), and screening can enable earlier AF detection and OAC initiation. However, the population-level trade-off between stroke prevention and OAC-related major bleeding for different types of AF and OAC therapy remains uncertain, and large randomized trials to resolve this are costly and time-consuming. Methods: A state-transition Markov-like model was developed to: 1) simulate the lifetime course of AF, stroke, major bleeding, and death in different virtual populations; 2) quantify benefits (stroke reduction) and harms (major bleeding) of systematic AF screening with screening-triggered OAC across CHA2DS2-VA scores; and 3) compare rhythm-guided, time-delimited ("pill-in-pocket") OAC with continuous OAC. Results: The model synthesized information from multiple clinical sources and reproduced stroke and bleeding incidence across clinical scenarios. At CHA?DS?-VA=2, long-term continuous rhythm monitoring (LT-CRM) with OAC lowered stroke risk (HR, 0.92 [95%CI, 0.88-0.96]) but raised bleeding risk (HR, 1.17 [95%CI, 1.07-1.27]) versus no screening. Time-to-benefit was shorter than time-to-harm for CHA?DS?-VA?4, but longer for CHA?DS?-VA=0. Pill-in-pocket OAC vs continuous OAC showed no difference in stroke/mortality (HR, 1.03, 95%CI [0.91-1.16]) but lower bleeding risk (HR, 0.81, 95%CI: 0.68-0.96]) in patients with elevated bleeding risk, but not at baseline. Sensitivity analyses revealed that the risk-benefit profiles of screening or pill-in-pocket OAC strategy further depend on OAC adherence and bleeding risks. Conclusions: Our model highlights a trade-off between stroke reduction and bleeding for systematic screening-initiated OAC, with net benefit for CHA?DS?-VA?4. We provide the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design. ### Competing Interest Statement U.S. received consultancy fees or honoraria from Università della Svizzera Italiana (USI, Switzerland), Roche Diagnostics (Switzerland), EP Solutions Inc. (Switzerland), Johnson & Johnson Medical Limited, (United Kingdom), Bayer Healthcare (Germany). U.S. is co-founder and shareholder of YourRhythmics BV, a spin-off company of the University Maastricht. M.R. received Consultancy fees from Bayer (OCEANIC-AF national PI), InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution, and Speaker fees from Daiichi-Sankyo, Pfizer to the institution. The other authors have nothing to declare. ### Clinical Trial not applicable for this modeling study ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: not applicable for this modeling study I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The model and all original code will be deposited at https://github.com/HeijmanLab/ to allow others to use and expand this novel approach. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.03.26367234v1 "Single-Cell Transcriptome-Wide Mendelian Randomization and Colocalization Analysis Reveals Immune Cell-Specific Mechanisms in Alzheimer's Disease")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.05.26367213v1 "Quantifying the contribution of policy measures to COVID-19 dynamics across 126 countries") Posted November 05, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/05/2026.11.04.26367324.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.04.26367324v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/05/2026.11.04.26367324.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Risk-benefit assessment of oral anticoagulation in atrial fibrillation using virtual clinical trials Minsi Cai, Fateme Farahani, Michiel Rienstra, Stefano Severi, Harry J.G.M. Crijns, Ulrich Schotten, Jordi Heijman medRxiv 2026.11.04.26367324; doi: https://doi.org/10.64898/2026.11.04.26367324 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.04.26367324v1%26text%3DRisk-benefit%2520assessment%2520of%2520oral%2520anticoagulation%2520in%2520atrial%2520fibrillation%2520using%2520virtual%2520clinical%2520trials "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.04.26367324v1%26t%3DRisk-benefit%2520assessment%2520of%2520oral%2520anticoagulation%2520in%2520atrial%2520fibrillation%2520using%2520virtual%2520clinical%2520trials "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.04.26367324v1%26title%3DRisk-benefit%2520assessment%2520of%2520oral%2520anticoagulation%2520in%2520atrial%2520fibrillation%2520using%2520virtual%2520clinical%2520trials%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.04.26367324v1%26title%3DRisk-benefit%2520assessment%2520of%2520oral%2520anticoagulation%2520in%2520atrial%2520fibrillation%2520using%2520virtual%2520clinical%2520trials "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.04.26367324) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.04.26367324v1&count=horizontal&via=&text=Risk-benefit%20assessment%20of%20oral%20anticoagulation%20in%20atrial%20fibrillation%20using%20virtual%20clinical%20trials&counturl=www.medrxiv.org/content/10.64898/2026.11.04.26367324v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (917) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (350) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4995) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (494) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (427) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (676) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1690) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16251) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1241) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7273) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (751) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1093) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5281) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1467) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1831) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1380) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16483) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1202) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (699) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (751) * [Neurology](https://www.medrxiv.org/collection/neurology) (7583) * [Nursing](https://www.medrxiv.org/collection/nursing) (377) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1127) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1295) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1039) * [Oncology](https://www.medrxiv.org/collection/oncology) (3742) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1092) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (407) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (465) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (500) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (721) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1858) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (755) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (785) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6122) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9981) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2528) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1515) * [Respiratory Medicine]
## Related Clinical Research

- [Rising stroke incidence in adults under 55 despite overall declines in the US](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rates-are-falling-overall-but-rising-among-adults-under-55.md)
- [Left atrial septal pouch (LASP): rediscovering heart anatomy and clinical implications](https://medichelpline.com/clinical-feed/stat-news-2-opinion-i-discovered-a-new-structure-in-the-heart-just-by-looking-closely.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years earlier](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)
- [Shingrix shingles vaccine associated with modestly lower cardiovascular risk in natural-experiment](https://medichelpline.com/clinical-feed/stat-news-0-newer-shingles-vaccine-linked-to-lower-heart-disease-risk-natural-experiment.md)
- [Increasing stroke risk in younger adults requires targeted prevention and updated risk assessment](https://medichelpline.com/clinical-feed/plos-medicine-0-stroke-risk-in-younger-age-groups-is-increasing-and-requires-targeted-prevention.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.